Allergy Shots Treatment: The Disease-Modifying Immunotherapy Overview
Allergy shots treatment is subcutaneous immunotherapy (SCIT) — a 3-to-5-year course of weekly-to-monthly allergen-extract injections designed to induce immune tolerance. Cochrane SMD −0.73 for seasonal AR (51 RCTs); NNT 3 to prevent asthma deterioration; 0.1% systemic-reaction rate per visit. NOT indicated for chronic urticaria (use Xolair) or food allergy. 23.9% of patients never return for their first injection.
8 peer-reviewed sources
Allergy shots treatment is SCIT — 24-28 weekly build-up injections then ongoing maintenance for 3-5 years, indicated for allergic rhinitis, asthma, and Hymenoptera venom allergy. Cochrane symptom SMD −0.73 across 51 RCTs. Not for chronic hives or food allergy.
The essentials
Allergy shots treatment — subcutaneous immunotherapy (SCIT) — is a 3-to-5-year course of weekly-to-monthly subcutaneous injections of allergen extracts designed to induce immune tolerance to specific IgE-sensitized allergens. It is the only FDA-recognized disease-modifying treatment for IgE-mediated allergic disease, codified in the US by Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034, AAAAI/ACAAI/JCAAI Practice Parameter Third Update). CMS LCD L36240 designates Cox 2011 PP3 as the operative coverage standard.
The "treatment" framing typically reflects patients researching their treatment plan options — often after antihistamines and intranasal steroids have proven insufficient.
Indications: allergic rhinitis/conjunctivitis, allergic asthma, Hymenoptera venom hypersensitivity (Cox 2011 PP3). Not first-line for food allergy or chronic urticaria. For chronic spontaneous urticaria, the FDA-approved targeted therapy is omalizumab (Xolair), an anti-IgE monoclonal antibody approved in 2014 — not SCIT. For food allergy, oral immunotherapy (OIT) and omalizumab (FDA-approved February 16, 2024 for multi-food allergy prevention, Wood RA et al., NEJM 2024;390:889-899, DOI 10.1056/NEJMoa2312382) are the current options — Palforzia (peanut OIT, FDA-approved 2020) is being commercially discontinued as of July 31, 2026.
Curex pairs at-home IgE testing with board-certified allergist review to determine which allergens are driving symptoms — the prerequisite diagnostic step before any allergy-shot treatment plan is built.
Treatment structure: build-up phase consists of approximately 24-28 weekly injections to reach maintenance dose (some patients on cluster protocols can complete build-up in 4-8 weeks with multiple injections per visit per Tabar AI et al., JACI 2005). Maintenance phase involves injections on a schedule individualized by your allergist for 3-5 years. Anatomical site: subcutaneous, upper outer arm posterolateral to the deltoid, alternating arms, 26-27G ½-inch needle (Cox 2011 PP3, Summary Statements 13-14). Mandatory 30-minute observation after each injection (Summary Statement 32; ~70% of severe reactions begin within this window).
Evidence summary: - Seasonal AR symptom SMD: −0.73 (95% CI −0.97 to −0.50) vs placebo (Calderón MA et al., Cochrane 2007, DOI 10.1002/14651858.CD001936.pub2; 51 RCTs, 2,871 patients) - Seasonal AR medication SMD: −0.57 (95% CI −0.82 to −0.33) vs placebo (Calderón 2007) - Asthma: NNT 3 to prevent one patient's asthma deterioration (Abramson MJ et al., Cochrane 2010, DOI 10.1002/14651858.CD001186.pub2; 88 SCIT trials) - VIT: 2.7% subsequent systemic sting reaction treated vs 39.8% untreated (Boyle RJ et al., Cochrane 2012, PMID 23076950) - Durability: ≥3-year post-treatment remission after 3-4 year course (Durham SR et al., NEJM 1999;341:468-475, DOI 10.1056/NEJM199908123410702) - Safety: 0.1% systemic-reaction rate per injection visit (Epstein TG et al., Ann Allergy Asthma Immunol PMID 23535092/24607043); ~1 fatality per 2.5M injections long-run (Bernstein DI et al., JACI 2004 12-year survey) - Cost-effectiveness: SCIT cost-effective vs pharmacotherapy from ~6 years after initiation (Cox L, Murphey A, Hankin C, Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122)
Dropout reality: Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957-965, DOI 10.1080/03007995.2021.1903848) found 23.9% of immunotherapy patients never returned for their first injection, and only 43.9% reached maintenance in a large commercial claims database (n=103,207). The access and adherence burden is real.
Curex's At-Home Allergy Shot Kit (SCIT) at $129/month addresses both barriers directly: the personalized serum is sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist, and self-administered as one weekly subcutaneous shot at home. A prescribed epinephrine auto-injector is confirmed on-hand before the first injection, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and gradual week-by-week escalation mirrors the same protocol used in clinics — making at-home maintenance possible for eligible patients without the 39-visit Year 1 clinic schedule.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
SCIT treatment proceeds in two main phases followed by a sustained post-treatment benefit period. The build-up schedule can be conventional, cluster, or rush — each with different time/risk tradeoffs. Note: Curex uses a conservative once-weekly build-up and does not offer rush or cluster schedules in the current pilot.
Injections begin at the lowest dilution and escalate in concentration and volume at each visit, targeting the maintenance dose. Conventional build-up: ~24-28 weekly visits (Cox 2011 PP3). Cluster build-up: 4-8 weeks with multiple injections per visit separated by 20-30 minutes (Tabar AI et al., JACI 2005). Rush: 1-3 days, multiple injections per day under close supervision (Bernstein DI et al., JACI 2008 — 5-15% systemic-reaction rate, primarily used for VIT or select research protocols).
Once maintenance dose is reached, injection frequency drops to on a schedule individualized by your allergist. Most patients notice meaningful symptom improvement within the first year of maintenance. Missing maintenance doses may require dose adjustment per the prescribing allergist's protocol. Most patients make 12-25 clinic visits per year during maintenance.
Standard recommendation is to complete 3-5 years of maintenance before discussing discontinuation (Cox 2011 PP3). Durham SR et al. (NEJM 1999;341:468-475) showed 3-4 year grass SCIT produced sustained remission for at least 3 further years post-discontinuation. Relapse ranges from ~0% (grass pollen) to ~55% (dust mite) over 5 years (Cox & Cohn 2007). Re-initiation is possible if relapse occurs.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Is allergy shots treatment right for me?
Allergy shots are most appropriate for patients with IgE-mediated allergic disease — confirmed by skin or blood testing — whose symptoms are not adequately controlled by pharmacotherapy, or who want to reduce long-term medication dependence. Indications include allergic rhinitis, allergic conjunctivitis, allergic asthma (when controlled), and Hymenoptera venom hypersensitivity (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). Contraindications include uncontrolled asthma, severe cardiovascular disease, and pregnancy initiation. Beta-blocker use requires individualized provider review and enhanced informed consent but is not an automatic exclusion. The practical assessment involves symptom severity, allergen-testing results, patient lifestyle (can weekly visits be accommodated?), and cost-insurance picture. A board-certified allergist is the appropriate person to make the candidacy assessment after reviewing your history and testing results.
How long does allergy shots treatment take?
Allergy shots treatment spans 3-5 years total — a build-up phase of approximately 24-28 weekly injections to reach maintenance dose, then a maintenance phase of maintenance injections for 3-5 years (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). Year 1 involves approximately 39 in-person visits. Cluster build-up protocols (Tabar AI et al., JACI 2005) can compress build-up to 4-8 weeks with multiple injections per visit, reducing Year 1 visit count but increasing per-visit time. After completing the full course, the disease-modifying benefit — sustained immune tolerance — persists for years to a decade-plus post-treatment (Durham SR et al., NEJM 1999). The upfront time investment of 3-5 years must be weighed against decades of reduced or eliminated allergy symptoms.
What is the success rate of allergy shots treatment?
Clinical trial data suggests 50-80% of patients with allergic rhinitis achieve clinically meaningful improvement on SCIT (Cox 2011 PP3). The Cochrane seasonal AR meta-analysis (Calderón 2007, 51 RCTs) found symptom SMD −0.73 versus placebo — a clinically meaningful effect comparable to or better than pharmacotherapy. For Hymenoptera venom allergy, the success rate is higher: >95% prevention of systemic sting reactions (Golden DBK et al., JACI 2005; Boyle 2012 Cochrane: 2.7% vs 39.8% untreated). In real-world data, only 43.9% of immunotherapy patients reached maintenance (Tkacz JP et al., Curr Med Res Opin 2021), reflecting the access and adherence gap — not all patients who would benefit complete the course.
Does allergy shots treatment work for chronic hives?
No — subcutaneous immunotherapy (SCIT) is not indicated for chronic spontaneous urticaria (CSU, chronic hives). Cox 2011 PP3 lists chronic urticaria as a non-indication for SCIT. The FDA-approved targeted therapy for CSU in patients ≥12 years who remain symptomatic on H1-antihistamines is omalizumab (Xolair), approved in 2014. The treatment pathway for CSU is: (1) second-generation H1 antihistamines at standard dose; (2) up-dose H1 antihistamines up to 4× standard; (3) omalizumab (Xolair) if symptoms persist. The only exception is urticaria from Hymenoptera (bee/wasp) sting anaphylaxis — for that specific scenario, venom immunotherapy (VIT) IS indicated and highly effective (Cochrane Boyle 2012: 2.7% vs 39.8% subsequent sting reaction).
Does allergy shots treatment work for food allergies?
Subcutaneous immunotherapy (SCIT) is NOT standard of care for food allergies. The historical reason: a 1992 peanut SCIT trial by Oppenheimer et al. produced fatalities and was abandoned. The current standard approach for IgE-mediated food allergy is oral immunotherapy (OIT) through specialized food-allergy centers, or avoidance. For multi-food allergy, omalizumab (Xolair) received FDA approval on February 16, 2024, for reducing reaction severity during accidental exposure (OUtMATCH trial: Wood RA et al., NEJM 2024;390:889-899, DOI 10.1056/NEJMoa2312382 — 67% protection vs 7% placebo). Palforzia (peanut OIT powder, FDA-approved 2020) is being commercially discontinued as of July 31, 2026.
What are the alternatives to allergy shots treatment?
The main disease-modifying alternatives to SCIT are: (1) Sublingual immunotherapy (SLIT) drops — custom allergen formulations prescribed by a board-certified allergist, taken daily as under-the-tongue drops at home; strong European evidence base comparable to SCIT for studied allergens; no needles or in-office visits after initial evaluation. (2) FDA-approved SLIT tablets — Grastek (grass), Oralair (5-grass mix), Ragwitek (ragweed), Odactra (dust mite) — approved for specific single-allergen sensitizations, first dose given in-office with observation. (3) Xolair (omalizumab) — for moderate-severe asthma, CSU, and multi-food allergy; biologic mechanism different from immunotherapy. (4) Pharmacotherapy — antihistamines and intranasal corticosteroids; effective for symptom control but not disease-modifying. The choice depends on allergen profile, lifestyle, and patient preference.
What is the dropout rate for allergy shots treatment?
Allergy shot dropout is a recognized clinical problem. Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957-965, DOI 10.1080/03007995.2021.1903848) analyzed the IBM MarketScan database (n=103,207 allergy immunotherapy patients, 2014-2017) and found 23.9% never returned for their first injection after the initial consultation, and only 43.9% ultimately reached the maintenance phase. Dropout is driven by multiple factors: geographic access (81.5% of US counties have zero allergists per Wu I et al., AAAAI 2019), time burden (39+ in-office visits in Year 1), insurance navigation complexity, and cost concerns — particularly HOPD facility fee exposure. For patients who cannot sustain the traditional in-clinic injection schedule, Curex's At-Home Allergy Shot Kit makes SCIT self-administered — one weekly subcutaneous shot at home for $129/month, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on-hand, and board-certified allergist oversight throughout the course.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreShot for Pollen Allergy: SCIT Guide | Curex
Shot for pollen allergy: SCIT with Cochrane SMD −0.73 (51 RCTs). Durham 1999: 3-yr grass course → 3+ yr remission. 7 FDA-standardized extracts listed.
Read moreAllergy Shots for Hives: SCIT vs Xolair | Curex Guide
Allergy shots (SCIT) not first-line for chronic hives — Xolair is (FDA 2014). Exception: venom shots (VIT) for Hymenoptera-triggered hives. Full guide.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreAllergy Shot Test: Skin Testing vs SCIT | Curex Guide
Allergy shot test = skin prick testing (CPT 95004, diagnostic). NOT the same as a SCIT shot (CPT 95117). HOPD test panels billed $24,400–$48,329.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.